‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid

So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for the worse following the Iran war and inflationary impacts.

CNBC • Jun 4, 2026

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • May 27, 2026

Biotech Investors Are Tuning Out the MAHA Chaos

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

WSJ • May 20, 2026

SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength

XBI continues to strengthen following a multi-month breakout, with bullish trend signals supporting upside targets near key Fibonacci retracement resistance levels.

FXEmpire • May 8, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

Locking In A Quick Gain In This Biotech ETF Made Room For Better Swing Trades; Here's Why

Locking in profits while you have them can help avoid downturns.

Investors Business Daily • May 1, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Zacks Investment Research • Apr 30, 2026

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now

Biotech has reasserted itself over the past year as drug approvals,

24/7 Wall Street • Apr 23, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research • Apr 22, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026